Zobrazeno 1 - 10
of 115
pro vyhledávání: '"Georg H, Fey"'
Autor:
Todd A. Braciak, Claudia C. Roskopf, Sarah Wildenhain, Nadja C. Fenn, Christian B. Schiller, Ingo A. Schubert, Uwe Jacob, Annemarie Honegger, Christina Krupka, Marion Subklewe, Karsten Spiekermann, Karl-Peter Hopfner, Georg H. Fey, Michael Aigner, Stefan Krause, Andreas Mackensen, Fuat S. Oduncu
Publikováno v:
OncoImmunology, Vol 7, Iss 9 (2018)
A number of agents designed for immunotherapy of Acute Myeloid Leukemia (AML) are in preclinical and early clinical development. Most of them target a single antigen on the surface of AML cells. Here we describe the development and key biological pro
Externí odkaz:
https://doaj.org/article/9c33b3300b544ab9bf536064eecde761
Publikováno v:
Antibodies, Vol 1, Iss 1, Pp 88-123 (2012)
Unmodified antibodies (abs) have been successful in the treatment of hematologic malignancies, but less so for the treatment of solid tumors. They trigger anti-tumor effects through their Fc-domains, and one way to improve their efficacy is to optimi
Externí odkaz:
https://doaj.org/article/06826a3a030a4fa1afec42ef082b9a29
Publikováno v:
Antibodies, Vol 1, Iss 1, Pp 2-18 (2012)
Here we review recombinant proteins with a capability for dual-targeting. These molecules address two different antigens on the same tumor cell and therefore are called “dual-targeting agents”. By virtue of binding a chosen pair of antigens on th
Externí odkaz:
https://doaj.org/article/8cd269b7b6f44bd8af2794ff92a1d442
Autor:
Ingo Schubert, Christina Krupka, Andreas Mackensen, Karsten Spiekermann, Annemarie Honegger, Sarah Wildenhain, Todd A. Braciak, Stefan W. Krause, Marion Subklewe, Nadja C. Fenn, Uwe Jacob, Christian B. Schiller, Georg H. Fey, Michael Aigner, Claudia C. Roskopf, Fuat Oduncu, Karl-Peter Hopfner
Publikováno v:
OncoImmunology, Vol 7, Iss 9 (2018)
Oncoimmunology
Oncoimmunology
A number of agents designed for immunotherapy of Acute Myeloid Leukemia (AML) are in preclinical and early clinical development. Most of them target a single antigen on the surface of AML cells. Here we describe the development and key biological pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08f15f5ec16fb9f8d9620efd3e57b652
https://doaj.org/article/9c33b3300b544ab9bf536064eecde761
https://doaj.org/article/9c33b3300b544ab9bf536064eecde761
Autor:
Michael Schwenkert, Gerold Schuler, Andreas Hombach, Hinrich Abken, Jan Dörrie, Beatrice Schuler-Thurner, Christian Krug, Alexander Paulus, Patrick Schmidt, Nicole Hoffmann, Georg H. Fey, Niels Schaft, Katrin Birkholz
Publikováno v:
Cancer Immunology, Immunotherapy. 64:1623-1635
Chimeric antigen receptor (CAR)-modified T cells emerged as effective tools in the immunotherapy of cancer but can produce severe on-target off-tissue toxicities. This risk can conceivably be overcome, at least partially, by transient transfection. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44ef0ae4e8ab3ac4e8c219695843ffea
https://doi.org/10.1007/s00262-015-1767-4
https://doi.org/10.1007/s00262-015-1767-4
Autor:
Karl-Peter Hopfner, Alexandra Schele, Ursula J.E. Seidel, Nadja C. Fenn, Annemarie Honegger, Christian B. Schiller, Todd A. Braciak, Sarah Wildenhain, Fuat Oduncu, Ingo Schubert, Kerstin Lämmermann, Peter Lang, Georg H. Fey, Claudia C. Roskopf, Uwe Jacob
Publikováno v:
Oncotarget
// Christian B. Schiller 1, * , Todd A. Braciak 2, * , Nadja C. Fenn 1, * , Ursula J. E. Seidel 3, * , Claudia C. Roskopf 2, * , Sarah Wildenhain 1, * , Annemarie Honegger * , Ingo A. Schubert 5 , Alexandra Schele 1 , Kerstin Lammermann 2 , Georg H.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f9594975ab5fee990d155d3a61be0db
https://pubmed.ncbi.nlm.nih.gov/27825135
https://pubmed.ncbi.nlm.nih.gov/27825135
Publikováno v:
Haematologica. 100:336-344
Current therapies for acute myeloid leukemia are associated with high failure and relapse rates. Adoptive immunotherapies, which have shown promise in the treatment of hematologic malignancies, have the potential to target acute myeloid leukemia thro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11aa499f6f01963b7ac65187563cc25e
https://doi.org/10.3324/haematol.2014.112748
https://doi.org/10.3324/haematol.2014.112748
Autor:
Todd A. Braciak, Sebastian Kobold, Fuat Oduncu, Karl-Peter Hopfner, Georg H. Fey, Christian B. Schiller, Claudia C. Roskopf, Ingo Schubert
Publikováno v:
Oncotarget
ResearcherID
ResearcherID
Triplebody 19-3-19, an antibody-derived protein, carries three single chain fragment variable domains in tandem in a single polypeptide chain. 19-3-19 binds CD19-bearing lymphoid cells via its two distal domains and primary T cells via its CD3-target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c13efc4aaf1957fda0ce2af7775f1e8b
https://doi.org/10.18632/oncotarget.2238
https://doi.org/10.18632/oncotarget.2238
Publikováno v:
mAbs. 6:286-296
The single-chain triplebody HLA-ds16-hu19 consists of three single-chain Fv (scFv) antibody fragments connected in a single polypeptide chain. This protein with dual-targeting capacity mediated preferential lysis of antigen double-positive (dp) over
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b52f3ef4454267461723f1b06b7bbd53
https://doi.org/10.4161/mabs.26768
https://doi.org/10.4161/mabs.26768